Press Releases Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
30.9 ^USD	+0.95%		+0.26%	-8.42%

May. 10	Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering	MT
May. 08	Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PACIRA BIOSCIENCES, INC. ANNOUNCES PRICING OF $250.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.125% CONVERTIBLE SENIOR NOTES DUE 2029	May. 13	AQ
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029	May. 10	GL
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029	May. 10	AQ
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes	May. 08	GL
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes	May. 08	AQ
Pacira BioSciences : 1Q 2024 Earnings Presentation	May. 07	PU
Pacira: Q1 Earnings Snapshot	May. 07	AQ
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program	May. 07	GL
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference	May. 07	GL
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024	Apr. 30	GL
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	GL
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	Mar. 20	AQ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	Mar. 13	GL
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	Mar. 13	AQ
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference	Mar. 06	GL
Pacira: Q4 Earnings Snapshot	Feb. 29	AQ
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results	Feb. 29	GL
Pacira to Report 2023 Financial Results on Thursday February 29, 2024	Feb. 22	GL
Pacira to Report 2023 Financial Results on Thursday February 29, 2024	Feb. 22	AQ
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy	Feb. 15	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Press Releases

Filters